Key result
This review summarizes the research history, pharmacology, and clinical development of growth hormone secretagogues for the treatment and diagnosis of growth hormone deficiency.
Why the study?
Several GHSs have been developed to treat or diagnose GH deficiency, alongside research identifying GHRH, GHS-R, and ghrelin, prompting a review of their research history, pharmacology, and clinical trials.
This review summarizes the research history, pharmacology, and clinical trials of growth hormone secretagogues.
GHSs for GH deficiency remain investigational; review leaves open questions on efficacy, safety, and clinical translation.
Growth hormone secretagogues (GHSs) are a generic term to describe compounds that increase growth hormone (GH) release. GHSs include agonists of the growth hormone secretagogue receptor (GHS‐R), whose natural ligand is ghrelin, and agonists of the growth hormone‐releasing hormone (GHRH) receptor, to which the GHRH binds as a native ligand. Several GHSs have been developed with a view to treating or diagnosing of GH deficiency, which causes growth retardation, gastrointestinal dysfunction, and altered body composition, in parallel with extensive research to identify GHRH, GHS‐R, and ghrelin. This review will focus on the research history and the pharmacology of each GHS, which reached randomized clinical trials. Furthermore, we will highlight the publicly disclosed clinical trials regarding GHSs.
No takes yet. Share an insight, caveat, or question.
Ishida et al. (2020) conducted a review in Growth hormone deficiency. Growth hormone secretagogues was evaluated. This review summarizes the research history, pharmacology, and clinical development of growth hormone secretagogues for the treatment and diagnosis of growth hormone deficiency.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: